CARIBOU BIOSCIENCES INC (CRBU) — insider trading
Health Care · NASDAQ
CARIBOU BIOSCIENCES INC (CRBU) has 20 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 20 (latest 2026-02-25).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P | Officer (Chief Technology Officer) | Open-market sale | 6,228 | $1.93 | $12.0K | Form 4 |
| 2026-02-24 | Albertson Tina M. | Officer (Chief Medical Officer) | Open-market sale | 1,066 | $1.96 | $2.1K | Form 4 |
| 2026-02-24 | Khan Ruhi Ahmad | Officer (Chief Business Officer) | Open-market sale | 6,938 | $1.96 | $13.6K | Form 4 |
| 2026-02-24 | MCCLUNG BARBARA G | Officer (Chief Legal Officer) | Open-market sale | 6,938 | $1.96 | $13.6K | Form 4 |
| 2026-02-24 | Kelly Timothy P | Officer (Chief Technology Officer) | Open-market sale | 3,147 | $1.96 | $6.2K | Form 4 |
| 2026-02-20 | Albertson Tina M. | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 247,500 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Albertson Tina M. | Officer (Chief Medical Officer) | Grant / award / vesting | 55,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Khan Ruhi Ahmad | Officer (Chief Business Officer) | Grant / award / vesting (derivative) | 202,500 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Khan Ruhi Ahmad | Officer (Chief Business Officer) | Grant / award / vesting | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | MCCLUNG BARBARA G | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 202,500 | $0.00 | $0 | Form 4 |
| 2026-02-20 | MCCLUNG BARBARA G | Officer (Chief Legal Officer) | Grant / award / vesting | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Kelly Timothy P | Officer (Chief Technology Officer) | Grant / award / vesting (derivative) | 202,500 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Kelly Timothy P | Officer (Chief Technology Officer) | Grant / award / vesting | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Braunstein Scott | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | GUGGENHIME ANDREW | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | JOHNSON DAVID LEE | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Richardson-Heron Dara | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Sacks Natalie | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Whiting Nancy | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
| 2026-02-20 | Zheng Ran | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
Ask the chat about CRBU's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CARIBOU BIOSCIENCES INC (CRBU).
Last updated 2026-02-25 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.